FDA approves Shire's extended-release ADHD drug

09/3/2009 | Reuters

The FDA approved Shire's Intuniv, an extended-release drug for attention-deficit/hyperactivity disorder in children ages 6 to 17. The British company said the drug, the first selective alpha-2A receptor agonist for ADHD, is expected to be available at U.S. pharmacies in November.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Diagnostic Technician
Marlborough, MA
Test Technician
Marlborough, MA
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ